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Drug Matrix cell B3: Practitioners; Medical treatment
S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  Quas i -randomisation reveals  methadone counsel lor i s  an ‘active ingredient’ (1988). Effectively random al location of patients  to di fferent methadone
counsel lors  at the same service revealed that effective counsel lors  were more di l igent and active, helping patients  anticipate problems and solutions.
S  What makes  a  methadone counsel lor effective? (1985). In US study di fferences  in effectiveness  could partly be explained by the personal i ties  of the therapists ,
particularly their abi l i ties  to quickly form warm, supportive relationships  with patients .
S  “Deviant” personal i ties  most effective methadone counsel lors  (1974). Patients  engaged better and used drugs  less  when their ex-addict counsel lors  shared their
insecuri ties  and edginess  and had a suspicious  outlook on l i fe. Simi lar findings  emerged from a study in England (2008) set in a  drug service for marginal ised
cl ients .
K  Treatment staff matter as  much as  the drug (1999). Trio of US studies  finds  methadone patients  do better with active counsel lors  who respond constructively to
their problems. One of the three was the study below.
K  Random al location exposes  impact of methadone counsel lors  (1999). US study started off investigating methadone dose but found that when tai lored to the
individual  i t made no di fference. What did make a big di fference to retention and i l legal  substance use (the two were related) was  which counsel lor the patient had
(essentia l ly at random) been ass igned to. One of three studies  featured in entry above.
K  Good relationship with doctor equals  more patients  sticking to just their prescribed methadone (2007). French study finds  that of a l l  the assessed variables
including dose, whether patients  fel t they had a good relationship with their doctors  was  most closely related to the el imination of non-prescribed opioid use s ix
months  later.
K  Patients  do best with GPs  who know them and communicate wel l  (2007). US patients  referred to primary care after detoxi fication reduced substance
use/problems most when they saw trusted doctors  who knew them as  a  whole person.
R  Cl inicians’ impact on treatment qual i ty (2000). Research relating retention and outcomes to profess ional  characteristics  of the cl inician: whether ex-addict,
adherence to protocols , countertransference, a l l iance, personal i ty, bel iefs  about treatment, and profess ional  practice issues.
G  What UK doctors  should do and be able to do ([UK] Royal  Col lege of Psychiatrists  and Royal  Col lege of General  Practi tioners , 2012). Guidance from UK
profess ional  associations  for GPs  and for psychiatrists  on the competencies , tra ining and qual i fications  expected of doctors  involved in caring for substance
users , from general is ts  such as  doctors  in emergency departments , to general  practi tioners  and addiction special is ts .
G  What UK special is t addiction doctors  should do and be able to do ([UK] Publ ic Health England, Royal  Col lege of Psychiatrists  and Royal  Col lege of General
Practi tioners , 2014). Guidance from body overseeing addiction treatment in England and from UK profess ional  associations  for GPs  and for psychiatrists  on the
part addiction special is ts  are expected to play in ensuring the best poss ible recovery outcomes for service users , and the importance of retaining their expertise in
the sector.
G  What US special is t addiction doctors  should do and be able to do ([US] American Society of Addiction Medicine, 2014). Consensus  guidel ines  from the US
profess ional  association for doctors  specia l is ing in treating addiction on what they are expected to do and the standards  they should meet at stages  in the
addiction care process  from assessment to aftercare.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page and hot topic on treatment staff.
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What is this cell about? About the treatment of dependence on illegal drugs in a medical context and/or involving medical care, typically
by GPs or hospital drug treatment units. Clinical staff are responsible for medications, so the centrality of these to an intervention
distinguishes it most clearly as medical. Medications may be intended to help patients withdraw from drugs, sustain longer term
abstinence, or to substitute a safer and medically controlled drug of the same kind more conducive to social stabilisation. But
medications are never all there is to medical care. Drug-based treatments require the collaboration of patients to take medications and
stay in or complete treatment, and interactions with staff are in themselves potentially therapeutic. Medical treatment may consist
entirely of advice and psychosocial support. All the seminal and key studies in this cell attest to the influence of relationships, even in
such a powerful pharmacological intervention as prescribing methadone to substitute for heroin. The relationship-forming qualities of
treatment staff are much less easily manipulated by researchers and less commonly researched than the intervention. Studies often have
to rely on an association between retention or substance use and relationship quality or staff attributes, rather than deliberately
allocating patients to workers known to differ along these dimensions. This makes it difficult to be confident that relationship quality or
staff attributes actually caused any differences in outcomes, rather than the reverse, or both being related to other factors.
Where should I start? With this freely available review, still a valuable introduction to the issues. It systematically runs through
evidence on the possible reasons why patients do better with one clinician than another. The reviewers comment that such effects often
emerge from studies which did not intend or expect to find them, in some having been strong enough to surface through the study’s
attempt to eliminate ‘extraneous’ influences. Relative neglect by research is contrasted with the everyday experience of front-line
clinicians, programme administrators, and patients, for whom it is “obvious ... that some practitioners are highly regarded whereas others
are avoided”. The reviewed research reveals that “clinicians typically account for more [of the difference] in patient outcomes than do
differences between active treatments or patients’ baseline characteristics”. What does not account for this impact is the clinician’s
professional characteristics, including whether they are themselves ex-addicts. According to the reviewers, the most consistent factor
has been the clinician’s ability to build a positive relationship with patients.
Highlighted study Philadelphia in the USA was the site one of those invaluable accidents which permit previously obscured influences to
come to light. We’ll describe it fairly fully because it seems the article is not freely available. It started with the sudden resignation of
two counsellors at a methadone service. Their caseloads were reassigned effectively at random to remaining counsellors, offering the
opportunity to see whether the four who got at least dozen new clients (61 in all were in the study) altered the trajectory of their progress
from the six months before to the six months after. Not only did this permit the counsellors to be compared with each other, it also meant
pre-transfer differences in the patients could be taken in to account by focusing on how they changed, not just where they ended up.
Clinic records were the data source in this study, which was led by the current adviser on addiction treatment to Public Health England.
Before the transfer each of the four sets of patients was spread across the counsellors who left, diluting the impact of the individual
counsellors, and each set was doing about equally well. After the transfer, each set was in the hands of a single counsellor, and the
impacts were huge. Despite higher methadone doses and more being prescribed other medications, patients transferred to the least
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effective counsellor worsened in their drug use, arrests and employment. In contrast, over a six-month period the most effective
counsellor was able to bring patients to the point where their non-prescribed drug use was virtually zero and employment significantly
improved, while at the same time substantially reducing their doses of methadone and the proportion prescribed ancillary medications.
Differences between patients and the qualifications of the counsellors did not account for the findings, which were also reflected in their
prior caseloads; before and after the transfer, they consistently differed from each other in how well their patients did. Case notes
indicated that all the good counsellors took a well organised and diligent approach to care planning, documentation and clinic rules, an
indication that good organisation is a fundamental platform for everything else to work, including relationship-building. The stand-out
counsellor built on this platform, anticipating patient problems and discussing strategies to deal with them in advance, focusing
counselling on the development of new behaviours and new ways of thinking. He or she was not only administratively diligent, but
actively problem-solving and therapeutic. The authors speculated that this enabled them not just to have better outcomes, but to achieve
these with less medication and less use of street drugs by their patients.
This was of course one small study, but the proposition that methadone counsellors alter the prospects of their patients is confirmed by
another larger US study involving 265 patients and 13 counsellors, which was also able to take advantage of quasi-random patient
allocation. It also seemed to emerge from this French study. In the Issues section below we consider one possible implication of these
findings.
Issues to think about
 What do rules do to relationships? First step in this bit of the bite is to gauge the importance of relationships; step two is to consider
the implications.
If you haven’t already, read the Highlighted study discussion. Then consider this quote from one of the cited studies: “Methadone dose ...
has been given too much emphasis ... the interpersonal processes involved in a working alliance with the substance-abusing patient and
the assigned therapist has been given too little” – a conclusion based on the finding that counsellors significantly differed in their
effectiveness, yet not because they authorised higher doses for their patients. Another cited study found the best counsellor actually
reduced doses relative to counsellors who did less well. Higher dosing is the most solidly established success factor in methadone
maintenance. If relationships are as important, then they are very important.
But it would be false to oppose dose and relationships and ask which is most important because almost certainly they interact.
Relationships may act partly through dose, permitting patients to feel they can be honest and open and enabling prescribers to flexibly
adjust dose in response to those messages, at least as important as the average dose level across a caseload (1 2). Patients who get the
doses they feel they need are likely to be easier to form relationships with and more positive about the clinic and the staff responsible for
their care.
However it happens, if relationships are important, that means influences on relationships too are important. In methadone programmes,
the most obvious are the sometimes unpalatable requirements which keyworkers and doctors must or choose to impose, including
patients having to come to the clinic or pharmacy nearly every day to swallow their methadone in front of staff, and regular urine tests to
spot unauthorised drug use. Both (especially supervision) have their justifications, but both too are easily seen as signs of a lack of trust
in the patient: in the first case, that they will take their medication as directed rather than selling or otherwise ‘diverting’ it; and in the
second, that their reports of their (non)substance use can be believed.
UK guidance de-emphasises urine testing and especially the undignified process of watching patients provide the specimen, but does
recommend supervised consumption for “around three months” and “longer in patients who fail to respond to conventional treatment.”
How do the patients see this unusual requirement? They may accept the rationale for supervision at the start of treatment, but more
extended supervision is generally unpopular. Asked specifically about guidance that methadone should be supervised for “at least 3–6
months”, 52% of patients in an English region disagreed and just 34% agreed. Doctors know patients find supervision aversive, so exploit
its relaxation or imposition to manipulate how patients behave; in Scotland, 20 out of 32 clinicians said they did this, and 13 felt
supervision led some patients to drop out prematurely. Supervision also entails near-daily attendance at the prescribing clinic or
pharmacy, in itself an unpopular requirement.
How do you think imposition of these requirements might affect relationships with keyworkers and doctors? Can they be implemented in
a sensitively skilled way which does not undermine the vital communication channel with the patient? From the Highlighted study, it
would seem so; remember all the most effective counsellors were diligent in this respect as in others. How might they have defused this
potential source of friction? Opinion, common sense and experience still rule on issues like this. Directly relevant research is noticeable
by its absence.
Thanks for their comments on this entry in draft to James Bell of the National Addiction Centre in London, England. Commentators bear no responsibility for the text
including the interpretations and any remaining errors.
Close Matrix Bite
Last revised 19 August 2014. Fi rst uploaded 01 June 2013
 Comment on this  entry
 Suggest a  new document to add to this  cel l
 Return to/go to Drugs  matrix
 Open Effectiveness  Bank home page and enter e-mai l  address  to be alerted to new studies
Drug Matrix cell B3: Practitioners; Medical treatment 19/08/14
http://findings.org.uk/count/downloads/download.php?file=Matrix/Drugs/B3.htm&format=open 2 / 2
